ECP treatment for early signs of lung transplant rejection
Part of Immune system & allergy clinical trials.
This trial tests whether a therapy called extracorporeal photopheresis (ECP) can stop early, silent rejection in lung transplant patients. It is for people who have developed donor-specific antibodies but still have normal lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received a double (bilateral) lung transplant.
- You have donor-specific antibodies that appeared more than 3 months after transplant and are at a certain level (MFI over 1000).
- Your new lungs are working well with no signs of rejection on tests.
- You were treated with a drug called alemtuzumab (a type of induction therapy) right after your transplant.
- You are not in another study, and you haven't had a retransplant or a multi-organ transplant.
- It has been 12 months or less since your lung transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
This study looks at whether blood tests and MRI scans can predict how well ECP (a blood-filtering treatment) works for people with CLAD after a lung transplant. If you’ve been prescribed ECP for CLAD and haven’t had it before, you may be able to help researchers find better ways to tailor treatment.
This study looks at how well extracorporeal photopheresis (a treatment that filters and treats your blood with light) works for kidney transplant patients who have antibody-mediated rejection (when your immune system attacks the new kidney). It may help doctors understand if this treatment can stop the rejection.
This trial looks at how “extracorporeal photochemotherapy” (a light-based treatment done outside the body) works at the cellular level. It may help improve treatment and control for people dealing with immune reactions after transplant or certain blood/skin conditions.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
Hear when a new Antibody-mediated Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.